Abstract
Thiazolidinediones, also known as glitazones, are insulin-sensitizing medications that account for approximately 21% of oral antihyperglycemic drugs used in the US. Although the main therapeutic effects occur in adipose tissue, muscles and the liver, studies suggest effects in bone as well. Currently, two thiazolidinediones are marketed in the US—rosiglitazone and pioglitazone—and several others are under investigation. This Review examines the evidence regarding the effects of thiazolidinediones on skeletal health. These drugs appear to trigger preferential differentiation of mesenchymal stem cells into adipocytes rather than osteoblasts, leading to decreased bone formation and increased adipogenesis. Although only a few small, randomized studies have examined the effects of thiazolidinediones on bone in humans, the available data suggest that these agents contribute to bone loss in postmenopausal women; the relationship is less clear in men. On the basis of this limited evidence, the absolute increase in fracture risk associated with thiazolidinediones seems to be small. Pending data from future randomized, controlled trials of the association between thiazolidinediones and low bone mass, prescribers should consider use of these drugs as a risk factor for the development of osteoporosis in postmenopausal women.
Key Points
-
Thiazolidinediones trigger preferential differentiation of mesenchymal stem cells into adipocytes rather than osteoblasts, leading to decreased bone formation and increased adipogenesis
-
Available evidence from clinical trials suggests that decreases in BMD are most notable in postmenopausal women taking thiazolidinediones
-
Clinicians should monitor BMD and other risk factors for osteoporosis during thiazolidinedione therapy
-
Osteoporosis therapy should be initiated in individuals who appear to be at increased risk of fracture, investigated by assessment of clinical risk factors and BMD testing
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Centers for Disease Control and Prevention (online 6 April 2007) Number (in millions) of persons with diagnosed diabetes, United States, 1980–2005 [http://www.cdc.gov/diabetes/statistics/prev/national/tablepersons.htm] (accessed 25 June 2008)
Rahman S et al. (2007) Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomized, double-blind, placebo-controlled study. Eur J Clin Pharmacol 63:733–741
Yokoyama J et al. (2007) Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 22: 146–151
Eguchi K et al. (2007) Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 30: 23–30
Dunaif A (2008) Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal. Nat Clin Pract Endocrinol Metab 4: 272–283
Glintborg D et al. (2008) Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 31: 328–334
Froment P and Touraine P (2006) Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS). PPAR Res 2006: 73986
Yki-Jarvinen H (2005) The PROactive study: some answers, many questions. Lancet 366: 1241–1242
Grey A et al. (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92: 1305–1310
Soroceanu MA et al. (2004) Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 183: 203–216
Ali AA et al. (2005) Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 146: 1226–1235
Okazaki R et al. (1999) Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 46: 795–801
Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18: 427–444
Holmberg AH et al. (2005) Risk factors for hip fractures in a middle-aged population: a study of 33,000 men and women. Osteoporos Int 16: 2185–2194
Forsen L et al. (1999) Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42: 920–925
Schwartz AV et al. (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86: 32–38
Nicodemus KK and Folsom AR (2001) Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 24: 1192–1197
Ottenbacher KJ et al. (2002) Diabetes mellitus as a risk factor for hip fracture in mexican american older adults. J Gerontol A Biol Sci Med Sci 57: M648–M653
Ahmed LA et al. (2006) Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 17: 495–500
de Liefde II et al. (2005) Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int 16: 1713–1720
Strotmeyer ES et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med 165: 1612–1617
Schwartz AV et al. (2005) Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res 20: 596–603
Schwartz AV et al. (2002) Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 25: 1749–1754
Vestergaard P et al. (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48: 1292–1299
Khan E and Abu-Amer Y (2003) Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med 142: 29–34
Lecka-Czernik B et al. (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74: 357–371
Kletzien RF et al. (1992) Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 41: 393–398
Mbalaviele G et al. (2000) Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J Biol Chem 275: 14388–14393
Okazaki R et al. (1999) Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140: 5060–5065
Odegaard JI et al. (2007) Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447: 1116–1120
Watanabe S et al. (2003) Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 21: 166–171
Cornish J et al. (2002) Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 175: 405–415
Cornish J et al. (1998) Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 275: E694–699
Cornish J et al. (1996) Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 59: 492–495
Lecka-Czernik B et al. (2007) Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 148: 903–911
Rubin GL et al. (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60: 1604–1608
Rzonca SO et al. (2004) Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401–406
Lazarenko OP et al. (2007) Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 148: 2669–2680
Sottile VK et al. (2004) Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 75: 329–337
Schwartz AV et al. (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91: 3349–3354
Berberoglu Z et al. (2007) Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92: 3523–3530
Lecka-Czernik B et al. (2002) Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 143: 2376–2384
FDA (2000) Withdrawal of troglitazone and cisapri. JAMA 283: 2228
Schwartz AV (2006) Diabetes, TZDs, and bone: a review of the clinical evidence. PPAR Res 2006: 24502
Yaturu SB et al. (2007) Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30: 1574–1576
Kahn SE et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443
Sanders KM et al. (1999) Age- and gender-specific rate of fractures in Australia: a population-based study. Osteoporos Int 10: 240–247
[No authors listed] (2007) Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS (pioglitazone HCl) tablets for type 2 diabetes mellitus. Deerfield, IL: Takeda
Li M et al. (2006) Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 39: 796–806
Lazarenko OP et al. (2006) Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone 38: 74–84
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RS Rosenthal has acted as a consultant or received honoraria from Bristol Myers/Sanofi, Daiichi Sankyo, GlaxoSmithKline, Merck and Novo Nordisk. KG Saag has received grants or research support from Amgen, Eli Lilly, Merck and Novartis. He has also acted as a consultant or received honoraria from Proctor & Gamble. The other authors declared no competing interests.
Rights and permissions
About this article
Cite this article
McDonough, A., Rosenthal, R., Cao, X. et al. The effect of thiazolidinediones on BMD and osteoporosis. Nat Rev Endocrinol 4, 507–513 (2008). https://doi.org/10.1038/ncpendmet0920
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0920
This article is cited by
-
Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in aging C57BL/6 mice and in vitro studies
Scientific Reports (2021)
-
Strontium in public drinking water and associated public health risks in Chinese cities
Environmental Science and Pollution Research (2021)
-
Moderate SMFs attenuate bone loss in mice by promoting directional osteogenic differentiation of BMSCs
Stem Cell Research & Therapy (2020)
-
Probiotics ameliorate pioglitazone-associated bone loss in diabetic rats
Diabetology & Metabolic Syndrome (2020)
-
Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes
Diabetologia (2017)